Dr Lalchandani Labs (BOM:541299) ROCE % : 0.32% (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Dr Lalchandani Labs ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dr Lalchandani Labs's annualized ROCE % for the quarter that ended in Sep. 2023 was 0.32%.

Dr Lalchandani Labs ROCE % Historical Data

The historical data trend for Dr Lalchandani Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Lalchandani Labs ROCE % Chart

Dr Lalchandani Labs Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

12.43

8.72

14.15

14.34

-5.30

Dr Lalchandani Labs Semi-Annual Data
	Mar13	Mar14	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROCE %	Get a 7-Day Free Trial													25.53	2.55	-6.91	-2.72	0.32

Dr Lalchandani Labs ROCE % Calculation

Dr Lalchandani Labs's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-6.801	/	( ( (181.236 - 48.611)	+	(177.187 - 53.201) )	/ 2 )
	=	-6.801	/	( (132.625	+	123.986)	/ 2 )
	=	-6.801	/	128.3055
	=	-5.30 %

Dr Lalchandani Labs's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	0.394	/	( ( (177.187 - 53.201)	+	(171.519 - 50.642) )	/ 2 )
	=	0.394	/	( ( 123.986	+	120.877 )	/ 2 )
	=	0.394	/	122.4315
	=	0.32 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

Dr Lalchandani Labs (BOM:541299) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dr Lalchandani Labs ROCE % Related Terms

Thank you for viewing the detailed overview of Dr Lalchandani Labs's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Lalchandani Labs (BOM:541299) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Dr Lalchandani Labs Ltd (BOM:541299) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Greater Kailash, Part-1, M-20, Basement, South Delhi, New Delhi, IND, 110048

Website

https://www.lalchandanipathlab.com

Dr Lalchandani Labs Ltd engages in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunology, virology, cytology, and other pathological and radiological investigations. It also offers Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA, and Genetic Testing. The company operates in two segments B2B sales and B2C sales, out of which the majority is from B2C sales. Revenue is generated from the sale of services.

Dr Lalchandani Labs (BOM:541299) Headlines

No Headlines